62507-46-4

Upstream product

• 100-02-7 4-nitro-phenol 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 64-17-5 ethanol 
• 24477-91-6 4-(4-nitro-phenoxy)-benzoyl chloride 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 16309-45-8 4-(4-nitrophenoxy)benzoic acid 
• 1415662-08-6 4-(4-(3-(3-methoxyphenyl)ureido)phenoxy)benzoic acid 
• 1415662-07-5 4-(4-(3-pyridin-2-ylureido)phenoxy)benzoic acid 
• 1415662-06-4 ethyl 4-(4-(3-(4-bromophenyl)ureido)phenoxy)benzoate 
• 1415662-05-3 ethyl 4-(4-(3-(4-chlorophenyl)ureido)phenoxy)benzoate 
• 1415662-04-2 ethyl 4-(4-(3-(4-methoxyphenyl)ureido)phenoxy)benzoate 
• 1415662-03-1 ethyl 4-(4-(3-(3-methoxyphenyl)ureido)phenoxy)benzoate 
• 1415662-02-0 ethyl 4-(4-(3-pyridin-2-ylureido)phenoxy)benzoate 
• 1415661-96-9 C₂₀H₁₆BrN₃O₄ 
• 1415661-95-8 C₂₀H₁₆ClN₃O₄ 
• 1415661-94-7 C₂₁H₁₉N₃O₅ 
• 1415661-93-6 C₂₁H₁₉N₃O₅ 
• 1415661-92-5 N-hydroxy-4-(4-(3-pyridin-2-ylureido)phenoxy)benzamide 
• 1415662-11-1 4-(4-(3-(4-bromophenyl)ureido)phenoxy)benzoic acid 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel benzoylimidazole derivatives as RAF and histone deacetylases dual inhibitors

In recent studies, combinations of histone deacetylases (HDACs) inhibitor with kinase inhibitor showed additive and synergistic effects. BRafV600E as an attractive target in many diseases treatments has been studied extensively. Herein, we pres

Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways

Guided by bioisosterism and pharmacokinetic parameters, we designed and synthesized a series of novel benzamide derivatives. Preliminary in vitro studies indicated that compounds 10b and 10j show significant inhibitory bioactivity in HepG2 cells (IC50 values of 0.12 and 0.13?μM, respectively). Compounds 10b and 10j induced the expression of HIF-1α protein and downstream target gene p21, and upregulated the expression of cleaved caspase-3 to promote tumor cells apoptosis.

SORAFENIB ANALOGS AND USES THEREOF

The present invention provides, inter alia, compounds according to formula I. Also provided are pharmaceutical compositions and kits containing such compounds. Methods for using such compounds, compositions, and kits for treating a subject having system xc-, dysregulation for activating ferroptosis, for inhibiting system xc- in a cell, and for monitoring treatment of a subject having system xc- dysregulation are provided as well.

Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors

A series of diaryl ether hydroxamic acids were synthesized for the first time and evaluated for the HDAC biology and antiproliferative activity. The structures of these new hydroxamic acids derivatives were confirmed by IR, 1H-NMR and mass spectrum. Some of these compounds showed micro molar activity in the HDAC inhibitory assay and against four cancer cell lines.

Easy Synthetic Approach to p-Aminophenoxy Derivatives Bearing Phosphonic or Carboxylic Ethyl Ester Groups

Condensation of the ethyl esters of phenyl carboxylic acids or phenyl-phosphonic acids with halonitrobenzenes in anhydrous acetonitrile in presence of potassium carbonate produces 4'-nitrophenoxy-benzoic or benzo-phosphonic acid ethyl esters in good yield